Reduced economic burden of AIDS-defining illnesses associated with adherence to antiretroviral therapy

Han Siong Toh, Chun Ting Yang, Kai Li Yang, Han Chang Ku, Chia Te Liao, Shihchen Kuo, Hung Jen Tang, Wen Chien Ko, Huang Tz Ou, Nai Ying Ko

研究成果: Article

摘要

Objectives: We assessed the economic burden of AIDS-defining illnesses (ADIs), which was further stratified by adherence to antiretroviral therapy (ART). Methods and materials: A nationwide longitudinal cohort of 18,234 incident cases with HIV followed for 11 years was utilized. Adherence to ART was measured by medication possession ratio (MPR). Generalized estimating equations modeling was used to estimate the cost impact of ADIs. Results: Having opportunistic infections increased the annual cost by 9% (varicella-zoster virus infection) to 98% (cytomegalovirus disease), while the annual costs increased by 26% (Kaposi's sarcoma) to 95% (non-Hodgkin's lymphoma) in the year when AIDS-related cancer occurred. ADIs occurred more frequently in the years with low adherence for ART compared to the high-adherence years (e.g., 0.1 ≤ MPR < 0.8 vs. MPR ≥ 0.8, event rate of cytomegalovirus disease 4.03% vs. 0.51%). The annual baseline costs in the years with MPR < 0.1, 0.1 ≤ MPR < 0.8, and MPR ≥ 0.8 were $250, $4,752, and $8,990 (in 2018 USD), respectively. The economic impact of ADIs in the years with low adherence (MPR < 0.1) was larger than that in the high-adherence years (MPR ≥ 0.8) (e.g., MPR < 0.1 vs. MPR ≥ 0.8, annual cost increased by 244% vs. 9% when candidiasis occurred). Conclusions: Adherence to ART may increase the baseline medical costs but mitigate the incidence and economic burden of ADIs.

原文English
頁(從 - 到)44-49
頁數6
期刊International Journal of Infectious Diseases
91
DOIs
出版狀態Published - 2020 二月

指紋

Acquired Immunodeficiency Syndrome
Economics
Costs and Cost Analysis
Medication Adherence
Cytomegalovirus
Therapeutics
Human Herpesvirus 3
Candidiasis
Kaposi's Sarcoma
Opportunistic Infections
Virus Diseases
Non-Hodgkin's Lymphoma
HIV
Incidence
Neoplasms

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

引用此文

Toh, Han Siong ; Yang, Chun Ting ; Yang, Kai Li ; Ku, Han Chang ; Liao, Chia Te ; Kuo, Shihchen ; Tang, Hung Jen ; Ko, Wen Chien ; Ou, Huang Tz ; Ko, Nai Ying. / Reduced economic burden of AIDS-defining illnesses associated with adherence to antiretroviral therapy. 於: International Journal of Infectious Diseases. 2020 ; 卷 91. 頁 44-49.
@article{5fecb677641e46f48bec65b98b85f119,
title = "Reduced economic burden of AIDS-defining illnesses associated with adherence to antiretroviral therapy",
abstract = "Objectives: We assessed the economic burden of AIDS-defining illnesses (ADIs), which was further stratified by adherence to antiretroviral therapy (ART). Methods and materials: A nationwide longitudinal cohort of 18,234 incident cases with HIV followed for 11 years was utilized. Adherence to ART was measured by medication possession ratio (MPR). Generalized estimating equations modeling was used to estimate the cost impact of ADIs. Results: Having opportunistic infections increased the annual cost by 9{\%} (varicella-zoster virus infection) to 98{\%} (cytomegalovirus disease), while the annual costs increased by 26{\%} (Kaposi's sarcoma) to 95{\%} (non-Hodgkin's lymphoma) in the year when AIDS-related cancer occurred. ADIs occurred more frequently in the years with low adherence for ART compared to the high-adherence years (e.g., 0.1 ≤ MPR < 0.8 vs. MPR ≥ 0.8, event rate of cytomegalovirus disease 4.03{\%} vs. 0.51{\%}). The annual baseline costs in the years with MPR < 0.1, 0.1 ≤ MPR < 0.8, and MPR ≥ 0.8 were $250, $4,752, and $8,990 (in 2018 USD), respectively. The economic impact of ADIs in the years with low adherence (MPR < 0.1) was larger than that in the high-adherence years (MPR ≥ 0.8) (e.g., MPR < 0.1 vs. MPR ≥ 0.8, annual cost increased by 244{\%} vs. 9{\%} when candidiasis occurred). Conclusions: Adherence to ART may increase the baseline medical costs but mitigate the incidence and economic burden of ADIs.",
author = "Toh, {Han Siong} and Yang, {Chun Ting} and Yang, {Kai Li} and Ku, {Han Chang} and Liao, {Chia Te} and Shihchen Kuo and Tang, {Hung Jen} and Ko, {Wen Chien} and Ou, {Huang Tz} and Ko, {Nai Ying}",
year = "2020",
month = "2",
doi = "10.1016/j.ijid.2019.11.010",
language = "English",
volume = "91",
pages = "44--49",
journal = "International Journal of Infectious Diseases",
issn = "1201-9712",
publisher = "Elsevier",

}

Reduced economic burden of AIDS-defining illnesses associated with adherence to antiretroviral therapy. / Toh, Han Siong; Yang, Chun Ting; Yang, Kai Li; Ku, Han Chang; Liao, Chia Te; Kuo, Shihchen; Tang, Hung Jen; Ko, Wen Chien; Ou, Huang Tz; Ko, Nai Ying.

於: International Journal of Infectious Diseases, 卷 91, 02.2020, p. 44-49.

研究成果: Article

TY - JOUR

T1 - Reduced economic burden of AIDS-defining illnesses associated with adherence to antiretroviral therapy

AU - Toh, Han Siong

AU - Yang, Chun Ting

AU - Yang, Kai Li

AU - Ku, Han Chang

AU - Liao, Chia Te

AU - Kuo, Shihchen

AU - Tang, Hung Jen

AU - Ko, Wen Chien

AU - Ou, Huang Tz

AU - Ko, Nai Ying

PY - 2020/2

Y1 - 2020/2

N2 - Objectives: We assessed the economic burden of AIDS-defining illnesses (ADIs), which was further stratified by adherence to antiretroviral therapy (ART). Methods and materials: A nationwide longitudinal cohort of 18,234 incident cases with HIV followed for 11 years was utilized. Adherence to ART was measured by medication possession ratio (MPR). Generalized estimating equations modeling was used to estimate the cost impact of ADIs. Results: Having opportunistic infections increased the annual cost by 9% (varicella-zoster virus infection) to 98% (cytomegalovirus disease), while the annual costs increased by 26% (Kaposi's sarcoma) to 95% (non-Hodgkin's lymphoma) in the year when AIDS-related cancer occurred. ADIs occurred more frequently in the years with low adherence for ART compared to the high-adherence years (e.g., 0.1 ≤ MPR < 0.8 vs. MPR ≥ 0.8, event rate of cytomegalovirus disease 4.03% vs. 0.51%). The annual baseline costs in the years with MPR < 0.1, 0.1 ≤ MPR < 0.8, and MPR ≥ 0.8 were $250, $4,752, and $8,990 (in 2018 USD), respectively. The economic impact of ADIs in the years with low adherence (MPR < 0.1) was larger than that in the high-adherence years (MPR ≥ 0.8) (e.g., MPR < 0.1 vs. MPR ≥ 0.8, annual cost increased by 244% vs. 9% when candidiasis occurred). Conclusions: Adherence to ART may increase the baseline medical costs but mitigate the incidence and economic burden of ADIs.

AB - Objectives: We assessed the economic burden of AIDS-defining illnesses (ADIs), which was further stratified by adherence to antiretroviral therapy (ART). Methods and materials: A nationwide longitudinal cohort of 18,234 incident cases with HIV followed for 11 years was utilized. Adherence to ART was measured by medication possession ratio (MPR). Generalized estimating equations modeling was used to estimate the cost impact of ADIs. Results: Having opportunistic infections increased the annual cost by 9% (varicella-zoster virus infection) to 98% (cytomegalovirus disease), while the annual costs increased by 26% (Kaposi's sarcoma) to 95% (non-Hodgkin's lymphoma) in the year when AIDS-related cancer occurred. ADIs occurred more frequently in the years with low adherence for ART compared to the high-adherence years (e.g., 0.1 ≤ MPR < 0.8 vs. MPR ≥ 0.8, event rate of cytomegalovirus disease 4.03% vs. 0.51%). The annual baseline costs in the years with MPR < 0.1, 0.1 ≤ MPR < 0.8, and MPR ≥ 0.8 were $250, $4,752, and $8,990 (in 2018 USD), respectively. The economic impact of ADIs in the years with low adherence (MPR < 0.1) was larger than that in the high-adherence years (MPR ≥ 0.8) (e.g., MPR < 0.1 vs. MPR ≥ 0.8, annual cost increased by 244% vs. 9% when candidiasis occurred). Conclusions: Adherence to ART may increase the baseline medical costs but mitigate the incidence and economic burden of ADIs.

UR - http://www.scopus.com/inward/record.url?scp=85076045268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076045268&partnerID=8YFLogxK

U2 - 10.1016/j.ijid.2019.11.010

DO - 10.1016/j.ijid.2019.11.010

M3 - Article

C2 - 31740407

AN - SCOPUS:85076045268

VL - 91

SP - 44

EP - 49

JO - International Journal of Infectious Diseases

JF - International Journal of Infectious Diseases

SN - 1201-9712

ER -